ATM and neoplasm: Combination of radiotherapy (RT) and kinase inhibitors of the DNA damage repair system (DDRi), targeting Ataxia Telangiectasia Mutated (ATM) or ATM and Rad3-related (ATR), are promising, but the consequences on tumor cell phenotype are still scarce.